Skip to main content
. 2015 Mar 11;5:9000. doi: 10.1038/srep09000

Figure 1. All animals were pre-treated with either the vehicle or the respective drug-transporter inhibitor (n = 6 for each treatment group) 30 minutes prior to drug treatment.

Figure 1

Plasma and brain samples were then collected from the animals 30 minutes after pioglitazone treatment. (A) Pioglitazone levels in plasma samples harvested from mice given i.p. pioglitazone with or without pre-treatment of LY335979 (P-gp blocker) and/or Ko143 (BCRP blocker). (B) Brain-to-plasma ratios of pioglitazone concentrations calculated for each mouse given i.p. pioglitazone with or without pre-treatment of LY335979 and/or Ko143. Error bar represents one SD. * P = 0.0287 and ** P = 0.0235 when compared against vehicle-only pre-treatment group.